# Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct05479812/  
OnCo record `nct05479812` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of WTX-124 run by Werewolf Therapeutics, Inc., completed.

## Summary

Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors is a phase 1 interventional study registered as NCT05479812 by Werewolf Therapeutics, Inc., with 156 participants enrolled, started 2022-08-15. Conditions recorded: Metastatic Solid Tumor and Advanced Solid Tumor. Interventions recorded: WTX-124 and pembrolizumab.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05479812
- Phase: 1
- Setting: A Multicenter Phase I/Ib Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced or Metastatic Solid Tumors
- Sponsor: Werewolf Therapeutics, Inc.
- Enrolled: 156

## Sources

- ClinicalTrials.gov NCT05479812: https://clinicaltrials.gov/study/NCT05479812

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [WTX-124](https://onco.cc/drugs/wtx-124/)
- companies: [Werewolf Therapeutics](https://onco.cc/companies/werewolf-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05479812.json